Your browser doesn't support javascript.
loading
Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?
Rajappa, Senthil; Rau, Kun-Ming; Dattatreya, Palanki Satya; Ramaswamy, Anant; Fernandes, Philana; Pruthi, Aarohan; Cheng, Rebecca; Lukanowski, Mariusz; Huang, Yi-Hsiang.
Afiliação
  • Rajappa S; Department of Medical Oncology, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad 500034, Telangana, India.
  • Rau KM; College of Medicine, I-Shou University, Kaohsiung 822, Taiwan.
  • Dattatreya PS; Department of Oncology, Omega Hospital, Hyderabad 500034, India.
  • Ramaswamy A; Department of Oncology, Tata Memorial Hospital, Mumbai 400012, India.
  • Fernandes P; Global Scientific Communications, Eli Lilly and Company Ltd, Cork 48006, Cork, Ireland.
  • Pruthi A; Medical Affairs, Eli Lilly India, Haryana 122001, India.
  • Cheng R; Medical Affairs, Eli Lilly Taiwan, Taipei 10543, Taiwan.
  • Lukanowski M; Medical Affairs, Eli Lilly, Herlev 2370, Denmark.
  • Huang YH; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Institute of Clinical Medicine, National Yang-Ming Yang Ming Chiao Tung University School of Medicine, Taipei 112, Taiwan. yhhuang@vghtpe.gov.tw.
World J Hepatol ; 14(6): 1074-1086, 2022 Jun 27.
Article em En | MEDLINE | ID: mdl-35978665
ABSTRACT
Hepatocellular carcinoma (HCC) is the most frequently diagnosed primary tumor of the liver and is usually detected as advanced disease. It is an aggressive disease that often progresses rapidly when it fails to respond to treatment. As such, patients have limited opportunities to try different subsequent-line treatment regimens. In the last 5 years, the number of agents and/or regimens available for the treatment of advanced HCC has significantly increased, which has made treatment choices for this patient population increasingly complex. In the second-line setting, several phase III trials of regorafenib (RESORCE), ramucirumab (REACH/REACH-2), and cabozantinib (CELESTIAL) have demonstrated clinically meaningful survival benefits in patients with the disease. However, the median overall survival of patients with advanced HCC remains unchanged at approximately 12 mo from the start of systemic second-line therapy, with a limited duration of response. Evidence from the REACH/REACH-2 trials demonstrated for the first time that baseline alpha-fetoprotein (AFP) levels can be used as an identification factor to select those who are likely to benefit the most from ramucirumab treatment. Ramucirumab is both well tolerated and efficacious and has a clinically acceptable safety profile. Therefore, it should be considered an option for patients with AFP levels ≥ 400 ng/mL.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: World J Hepatol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Índia

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: World J Hepatol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Índia